Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
UBS
Fuji
AstraZeneca
McKesson
QuintilesIMS
US Department of Justice
McKinsey
Citi

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201923

« Back to Dashboard

NDA 201923 describes ILUVIEN, which is a drug marketed by Alimera Sciences Inc and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the ILUVIEN profile page.

The generic ingredient in ILUVIEN is fluocinolone acetonide. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.
Summary for 201923
Pharmacology for NDA: 201923
Medical Subject Heading (MeSH) Categories for 201923
Suppliers and Packaging for NDA: 201923
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923 NDA Alimera Sciences, Inc. 68611-190 N 68611-190-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:IMPLANT;INTRAVITREALStrength0.19MG
Approval Date:Sep 26, 2014TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Mar 22, 2019Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF DIABETIC MACULAR EDEMA
Patent:➤ Try a Free TrialPatent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF DIABETIC MACULAR EDEMA
Patent:➤ Try a Free TrialPatent Expiration:Mar 22, 2019Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF DIABETIC MACULAR EDEMA

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
Federal Trade Commission
Colorcon
Cipla
Cerilliant
Queensland Health
Boehringer Ingelheim
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.